What’s the current market cap for Organon stock?

Organon (OGN) has a market cap of $3.5B as of June 03, 2026.

What is the P/E ratio for Organon stock?

The price to earnings (P/E) ratio for Organon (OGN) stock is 14.18 as of June 03, 2026.

Does Organon stock pay dividends?

Yes, the Organon (OGN) stock pays dividends to shareholders. As of June 03, 2026, the dividend rate is $0.08 and the yield is 0.6%. Organon has a payout ratio of 8.94% on a trailing twelve-month basis.

When is the next Organon dividend payment date?

The next Organon (OGN) dividend payment is scheduled for June 11, 2026.

What is the beta indicator for Organon?

Organon (OGN) has a beta rating of 1.55. This means that it is more volatile than the market, on average. A beta of 1 would indicate the stock moves in-line with the market, while a beta of 2 would indicate the stock moves twice as much as the market.

Buy Organon stock | $OGN Share Price

About Organon

Organon & Cois a globalised healthcare company with a mission to deliver impactful medicines and solutions for a healthier every day. Its operations include the following product portfolios: Women's Health: Itbwomen's health portfolio of products is sold by prescription mainly in two therapeutic areas: contraception, with key brands such as Nexplanon, and fertility, with key brands such as Follistim. other women's health products include the Jada, which is intended to provide control and treatment of abnormal postpartum uterine bleeding or hemorrhage when conservative management is warranted. The General Medicines portfolio includes biosimilars and established brands. Companies' current biosimilars portfolio spans across immunology and oncology-related treatments.

Ticker

$OGN

Sector

Health

Primary listing

NYSE

Employees

10,000

Headquarters

Jersey City, United States

Website

www.organon.com

Organon Metrics

BasicAdvanced

$3.5bn

14.18

$0.94

1.55

$0.08

0.60%

What the Analysts think about Organon

Analyst ratings (Buy, Hold, Sell) for Organon stock.

Bulls say / Bears say

Biosimilars revenue grew 23% as reported (21% ex-FX) in Q1 2026, driven by strong U.S. demand for Hadlima and contributions from recently approved biosimilars Bildyos, Bilprevda, and Tofidence (Business Wire)

Organon agreed to be acquired by Sun Pharmaceutical for $14.00 per share in an all-cash transaction valuing the company at $11.75 billion—a premium of about 103% over pre-announcement levels, unlocking substantial value for shareholders (Reuters)

Organon maintains solid liquidity with $1.12 billion in cash and equivalents, and has declared a quarterly dividend of $0.02 per share, demonstrating its commitment to shareholder returns even as the merger approaches (Business Wire)

Women’s Health revenue fell 16% as reported (19% ex-FX) in Q1 2026, including a 28% decline in U.S. Nexplanon sales due to delayed reinsertion cycles and uncertainty around federal funding (Business Wire)

Following the announced merger, Organon suspended its financial guidance and canceled its quarterly earnings call, lowering transparency about its near-term outlook and key performance drivers (Business Wire)

As of March 31, 2026, Organon held $8.57 billion in debt, far outweighing its $1.12 billion in cash and equivalents, signaling high financial leverage and potentially limiting strategic options before the merger closes (Business Wire)

Data summarised monthly by Lightyear AI. Last updated on 20 May 2026.

Organon Financial Performance

Revenues and expenses

QuarterlyAnnual

Q3 24

QoQ growth

Revenue

$37bn

-39.75%

Net income

$45bn

107.52%

Profit margin

37.65%

6.78%

Organon Earnings Performance

Company profitability

QuarterlyAnnual

Q4 23

Q1 24

Q2 24

Q3 24

Q4 24

Actual

$3.69

$2.85

$2.45

$2.42

-

Expected

$3.55

$2.61

$2.05

$2.31

$3.94

Surprise

3.94%

9.20%

19.51%

4.63%

-

Organon News

AllArticlesVideos

SHAREHOLDER NOTICE: Brodsky & Smith Announces an Investigation of Organon & Co. (OGN)

Newsfile Corp·10 hours ago

Organon to Present New Research on Access and Value at ISPOR 2026

Business Wire·3 weeks ago

Organon Reports Results for the First Quarter Ended March 31, 2026

Business Wire·1 month ago

Data displayed above is indicative only and its accuracy or completeness is not guaranteed. Actual execution price may vary. Past performance is not indicative of future results. Your return may be affected by currency fluctuations and applicable fees and charges. Capital at risk.

Real-time US market data is sourced from the IEX order book provided by Polygon. After-hours US market data is 15 minutes delayed and may differ significantly from the actual tradable price at market open.